<DOC>
	<DOC>NCT01031680</DOC>
	<brief_summary>This study is carried out to assess whether dapagliflozin lowers blood glucose, body weight and blood pressure, when added to patients existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes, cardiovascular disease and hypertension.</brief_summary>
	<brief_title>Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Type 2 diabetes mellitus. Cardiovascular disease Hypertension Patients with type 1 diabetes or diabetes insipidus Patients with 3 or more oral antihyperglycaemic drugs with or without insulin and/or poorly controlled diabetes Any clinically significant illness, which would compromise the patient's safety and their participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>dapagliflozin</keyword>
	<keyword>diabetes</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>hypertension</keyword>
</DOC>